There are no apparent biologic obstacles to immunization against fetal/placental infection
with cytomegalovirus (CMV), and vaccine candidates have been developed. The major
obstacles for a human CMV vaccine are difficulties associated with the design and execution
of efficacy trials. These trials will be prolonged with difficulties in recruiting subjects, and
hampered by several factors: First is a lack of public awareness of CMV, making recruitment
into vaccine trials difficult. Second is that trials using fetal infection as an endpoint will be …